Archived Investigations
ADMA Biologics, Inc. (NasdaqGM: ADMA)
According to the Complaint, ADMA Biologics and certain of its executives are charged with failing to disclose material information in the Offering Documents, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company engaged in an undisclosed related party transaction; (ii) the Company used channel stuffing to create an appearance of revenue; (iii) the Company lacked adequate internal controls; (iv) as a result, Defendants’ statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
The case is Mazzarino v. ADMA Biologics, Inc., et al, No. 26-cv-04793.